Sign In
Buy PULM
$1.29
-0.0300 (-2.27%)
At Close: Jun 03, 2026
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
08:05am, Thursday, 15'th May 2025
Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its asse
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix,
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
08:05am, Friday, 21'st Mar 2025
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
08:00am, Friday, 15'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or b
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix,
PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger
05:30pm, Thursday, 14'th Nov 2024
WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Pulmatrix, Inc. ("Pulmatrix") (NASDAQ CM:PULM) regarding possible breaches of fiduciary duties and other violatio
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM
05:13pm, Thursday, 14'th Nov 2024
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
07:39am, Thursday, 14'th Nov 2024
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders
09:53pm, Wednesday, 13'th Nov 2024
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Pulmatrix (Nasdaq: PULM) for possible breaches of fiduciary duty and other violations of law in its transaction with Cullgen. Click here to learn
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders
10:25am, Wednesday, 13'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Cullgen Inc. is fair to Pulmatrix shareholders. Upon
Pulmatrix and Cullgen Announce Proposed Merger
09:00am, Wednesday, 13'th Nov 2024
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of c
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
10:26am, Friday, 08'th Nov 2024
Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
09:05am, Tuesday, 13'th Aug 2024
Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
08:45am, Wednesday, 29'th May 2024
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
09:35am, Wednesday, 15'th May 2024
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improve
